The FAS -670A>G polymorphism influences susceptibility to systemic sclerosis phenotypes

Arthritis and Rheumatism

Volumn 60, Issue 12, 2009, Pages 3815-3820

  Broen, J ^a   Gourh, P ^b   Rueda, B ^c   Coenen, M ^a   Mayes, M ^b   Martin, J ^c   Arnett, F C ^b   Radstake, T R D J ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b UNIVERSITY OF TEXAS   (United States)

^c INSTITUTO DE PARASITOLOGÍA Y BIOMEDICINA LÓPEZ NEYRA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

CENTROMERE ANTIBODY;

ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; CORRELATION ANALYSIS; EUROPE; EUROPEAN AMERICAN; FAS GENE; GENE; GENE FREQUENCY; GENETIC POLYMORPHISM; GENETIC SUSCEPTIBILITY; GENOTYPE; GERMANY; HUMAN; ITALY; MAJOR CLINICAL STUDY; NETHERLANDS; PHENOTYPE; PRIORITY JOURNAL; RACE; RISK FACTOR; SINGLE NUCLEOTIDE POLYMORPHISM; SWEDEN; SYSTEMIC SCLEROSIS;

ADENOSINE; ANTIGENS, CD95; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; GUANOSINE; HUMANS; MALE; MIDDLE AGED; PHENOTYPE; POLYMORPHISM, SINGLE NUCLEOTIDE; PROMOTER REGIONS, GENETIC; SCLERODERMA, DIFFUSE; SCLERODERMA, LIMITED;

EID: 73249130667     PISSN: 00043591     EISSN: 15290131     Source Type: Journal    
DOI: 10.1002/art.24964     Document Type: Article

References (16)

1. LeRoy EC, Black C, Fleischmajer R, Jablonska S, Krieg T, Medsger TA Jr, et al. Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. J Rheumatol 1988;15:202-5.
2. Roumm AD, Whiteside TL, Medsger TA Jr, Rodnan GP. Lymphocytes in the skin of patients with progressive systemic sclerosis: quantification, subtyping, and clinical correlations. Arthritis Rheum 1984;27:645-53.
3. Cipriani P, Fulminis A, Pingiotti E, Marrelli A, Liakouli V, Perricone R, et al. Resistance to apoptosis in circulating α/β and γ/δ T lymphocytes from patients with systemic sclerosis. J Rheumatol 2006;33:2003-14.
4. Wetzig T, Petri JB, Mittag M, Haustein UF. Serum levels of soluble Fas/APO-1 receptor are increased in systemic sclerosis. Arch Dermatol Res 1998;2904:187-90.
5. Kanemitsu S, Ihara K, Saifddin A, Otsuka T, Takeuchi T, Nagayama J, et al. A functional polymorphism in fas (CD95/APO-1) gene promoter associated with systemic lupus erythematosus. J Rheumatol 2002;29:1183-8.
6. Wasfi YS, Silveira LJ, Jonth A, Hokanson JE, Fingerlin T, Sato, H et al. Fas promoter polymorphisms: genetic predisposition to sarcoidosis in African-Americans. Tissue Antigens 2008;721: 39-48.
7. Agarwal K, Czaja AJ, Donaldson PT. A functional Fas promoter polymorphism is associated with a severe phenotype in type 1 autoimmune hepatitis characterized by early development of cirrhosis. Tissue Antigens 2007;69:227-35.
8. Van Veen T, Kalkers NF, Crusius JB, van Winsen L, Barkhof F, Jongen PJ, et al.The FAS-670 polymorphism influences susceptibility to multiple sclerosis. J Neuroimmunol 2002;128:95-100.
9. Liakouli V, Manetti M, Pacini A, Tolusso B, Fatini C, Toscano A, et al. The -670G>A polymorphism in the FAS gene promoter region influences the susceptibility to systemic sclerosis. Ann Rheum Dis 2009;68:584-90.
10. Zhang H, Sun XF, Synnerstad I, Rosdahl I. Importance of FAS-1377, FAS-670, and FASL-844 polymorphisms in tumor onset, progression, and pigment phenotypes of Swedish patients with melanoma: a case-control analysis. Cancer J 2007;13:233-7.
11. Sibley K, Rollinson S, Allan JM, Smith AG, Law GR, Roddam PL, et al. Functional FAS promoter polymorphisms are associated with increased risk of acute myeloid leukemia. Cancer Res 2003; 6315:4327-30.
12. Subcommittee for Scleroderma Criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Arthritis Rheum 1980;23:581-90.
13. Mahfoudh W, Bel H Jr., Romdhane A, Chouchane L. A polymorphism in FAS gene promoter correlated with circulating soluble FAS levels. Int J Immunogenet 2007;34:209-12.
14. Rueda B, Broen J, Simeon C, Hesselstrand R, Diaz B, Suarez H, et al. The STAT4 gene influences the genetic predisposition to systemic sclerosis phenotype. Hum Mol Genet 2009;18:2071-7.
15. Nasi M, Pinti M, Bugarini R, Troiano L, Lugli E, Bellodi C, et al. Genetic polymorphisms of Fas (CD95) and Fas ligand (CD178) influence the rise in CD4+ T cell count after antiretroviral therapy in drug-naive HIV-positive patients. Immunogenetics 2005;57: 628-35.
16. Andreoli V, Nicoletti G, Romeo N, Condino F, La Russa A, Liguori M, et al. Fas antigen and sporadic Alzheimer's disease in Southern Italy: evaluation of two polymorphisms in the TNFRSF6 gene. Neurochem Res 2007;32:1445-9.